Eli Lilly and Company to acquire Sangamo Therapeutics, Inc.

Eli Lilly and Company has agreed to acquire specific assets from Sangamo Therapeutics, Inc. in a cash transaction valued at $50 million. The deal structure involves the purchase of selected business units rather than a full equity acquisition of the target company. This asset sale was announced on 8 September 2026, with the transaction having been completed four days prior on 4 September 2026. Both parties are based in the United States, operating within the healthcare sector. The consideration for this acquisition is provided entirely in cash, reflecting a straightforward financial arrangement without equity components or complex earn-out structures. This move allows Eli Lilly to integrate specific technologies or product lines from Sangamo directly into its existing portfolio.

The transaction represents a strategic expansion for the buyer into targeted therapeutic areas managed by the seller. By acquiring these assets, Eli Lilly gains immediate access to Sangamo’s intellectual property and development pipelines. The completion date indicates that all necessary regulatory approvals and internal board consents were secured before the public announcement. This timing suggests a streamlined due diligence process or pre-arranged terms between the two entities. The deal concludes with the assets officially transferring ownership from Sangamo Therapeutics to Eli Lilly and Company. The transaction is now fully executed and integrated into the buyer’s operations.